A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• The treatment of metastatic castration-resistant prostate cancer (mCRPC) has advanced with novel agents, including poly-ADP ribose polymerase (PARP) inhibitors.
• These inhibitors target DNA damage repair mutations, particularly homologous recombination repair (HRR) genes.

Purpose of the Study:

• To provide evidence-based answers for clinical questions regarding treatment selection and sequencing in mCRPC.
• To guide clinicians on optimizing genetic testing, counseling, and patient management in the era of PARP inhibitors.

Main Methods:

• This is a review article synthesizing current evidence.
• It addresses treatment selection, sequencing patterns, and decision-making factors.
• It also focuses on genetic testing and counseling strategies.

Main Results:

• The PROfound study confirmed PARP inhibitor sensitivity across various HRR mutations in mCRPC.
• Genomic testing is vital for identifying patients who may benefit from PARP inhibitors.
• The response of patients with rarer HRR mutations to PARP inhibitors requires further investigation.

Conclusions:

• Appropriate combination and sequencing of novel and existing therapies are essential for optimizing mCRPC management.
• Real-world data from future registry-based trials will be crucial for robust clinical decision-making.
• Further research is needed to clarify the efficacy of PARP inhibitors in patients with rarer HRR mutations.